Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic fever. The virus is endemic in over 120 countries, causing over 350 million infections per year.
Dengue vaccine development is challenging because of the need to induce simultaneous protection against four antigenically distinct DENV serotypes and evidence that, under some conditions, vaccination can enhance disease due to specific immunity to the virus. While several live-attenuated tetravalent dengue virus vaccines display partial efficacy, it has been challenging to induce balanced protective immunity to all 4 serotypes. Instead of using whole-virus formulations, we are exploring the potentials for a particulate subunit vaccine, based on DENV E-protein displayed on nanoparticles that have been precisely molded using Particle Replication in Non-wetting Template (PRINT) technology.
Here we describe immunization studies with a DENV2-nanoparticle vaccine candidate. The ectodomain of DENV2-E protein was expressed as a secreted recombinant protein (sRecE), purified and adsorbed to poly (lactic-co-glycolic acid) (PLGA) nanoparticles of different sizes and shape. We show that PRINT nanoparticle adsorbed sRecE without any adjuvant induces higher IgG titers and a more potent DENV2-specific neutralizing antibody response compared to the soluble sRecE protein alone. Antigen trafficking indicate that PRINT nanoparticle display of sRecE prolongs the bio-availability of the antigen in the draining lymph nodes by creating an antigen depot. Our results demonstrate that PRINT nanoparticles are a promising platform for delivering subunit vaccines against flaviviruses such as dengue and Zika.
Dengue virus (DENV) is transmitted by mosquitoes and is endemic in over 120 countries, causing over 350 million infections yearly. Most infections are clinically unapparent, but under specific conditions, dengue can cause severe and lethal disease. DENV has 4 distinct serotypes and secondary DENV infections are associated with hemorrhagic fever and dengue shock syndrome. This enhancement of infection complicates vaccine development and makes it necessary to induce protective immunity against all 4 serotypes. Since whole virus vaccine candidates struggle to induce protective immunity, we are developing a nanoparticle display vaccine approach. We have expressed, purified and characterized a soluble recombinant E-protein (sRecE). Regardless of nanoparticle shape or size, particulation of sRecE enhances DENV specific IgG titers and induces a robust, long lasting neutralizing antibody response and by adsorbing sRecE to the nanoparticles, we prolong the exposure of sRecE to the immune system.
Nanoparticle display shows great promise in dengue vaccine development and possibly other mosquito-borne viruses like zika virus.
The Latest on: Nanoparticle vaccines
via Google News
The Latest on: Nanoparticle vaccines
- Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturingon May 12, 2020 at 6:19 am
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Coalition for Epidemic Preparedness Innovations ...
- Novavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Serieson May 12, 2020 at 6:19 am
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today.
- Efforts Accelerated to Quickly Find Effective Treatment and Vaccine to Prevent Coronaviruson May 12, 2020 at 5:52 am
The latest strategic attack on the coronavirus resembles a war time scenario. When generals find a weaknesses in the enemy's lines, it ...
- CEPI Gives Novavax Up to $384M for COVID-19 Vaccine R&D, Manufacturingon May 12, 2020 at 5:00 am
The Coalition for Epidemic Preparedness Innovations (CEPI) will provide Novavax with up to $384 million in additional funding toward clinical development and large-scale manufacturing of the company’s ...
- T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titerson May 11, 2020 at 8:17 am
An HIV vaccine that elicits both antibodies and cellular immune responses confers long-lasting protection against viral challenge in nonhuman primates.
- Entos and Precision NanoSystems partner to enable GMP manufacturing of DNA COVID-19 vaccineon May 7, 2020 at 7:03 am
Entos is developing Covigenix; a pan-coronavirus Fusogenix DNA vaccine to address COVID-19 and future threats. Entos has partnered with Precision NanoSystems to incorporate their NanoAssemblr GMP ...
- Hunt for a coronavirus vaccine heats up, but there’s no guarantee of successon May 5, 2020 at 3:00 pm
Hundreds of people are volunteering to be injected with experimental vaccines that might stop COVID-19, but there's no guarantee any of them will work.
- COVID-19 vaccine hunt heats up globally, still no guaranteeon May 4, 2020 at 11:04 pm
Hundreds of people are rolling up their sleeves in countries across the world to be injected with experimental vaccines that might stop COVID-19, spurring hope — maybe unrealistic — that an end to the ...
- The Vaccine Factory Inside You: RNA Vaccine Basicson May 4, 2020 at 10:03 am
As the world pulls back from the acute phase of the COVID-19 pandemic, it enters what will be perhaps a more challenging time: managing the long-term presence of the SARS-CoV-2 virus that causes ...
via Bing News